ArticleMolecular therapy. Methods & clinical development2025

Repeat length as a key determinant for disease severity and antisense oligonucleotide activity in myotonic dystrophy type 1.

Najoua El Boujnouni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.